Studies radiation plus PD-1 immunotherapy for metastatic kidney cancer
Observes radiation to one tumor with PD-1 immunotherapy in adults with kidney cancer.
Key facts
- Who runs it
- Nanfang Hospital, Southern Medical University
- Where
- Guangzhou, ChinaSee the site
- Trial code
- Registry title
- Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 1 Oct 2023
- Planned end
- 30 Jun 2025
- Type of study
- Observational
- Record updated
- 25 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV kidney cancer (renal cell carcinoma) who already had stereotactic body radiation therapy (SBRT) together with PD-1 blockade treatment.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Advanced renal cell carcinoma, stage IV (AJCC 8), confirmed by tissue examination, with measurable metastases by RECIST 1.1 criteria.
- Earlier treatment
- Must have already received SBRT and PD-1 blockade treatment at the same time.
Main reasons for not taking part
- Cannot be adequately followed up
- Has another cancer that is progressing or needs active treatment
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age≥18 years at the time of signing informed consent
- Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8)
- Previously received SBRT and concurrent PD-1 blockade treatment；
- Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria
Who cannot take part
- Has a known additional malignancy that is progressing or requires active treatment
- Patients who cannot be adequately followed up
Where in China
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaContact: Guozhu XieTaking people
About the trial
What the trial wants to find out
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study
- Plain-language title
- Studies radiation plus PD-1 immunotherapy for metastatic kidney cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 May 2025